Grifols (Grifols) Equity-to-Asset

: 0.28 (As of Sep. 2023)

View and export this data going back to 2011. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Grifols's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $6,539 Mil. Grifols's Total Assets for the quarter that ended in Sep. 2023 was $23,548 Mil. Therefore, Grifols's Equity to Asset Ratio for the quarter that ended in Sep. 2023 was 0.28.

The historical rank and industry rank for Grifols's Equity-to-Asset or its related term are showing as below:

GRFS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.28 Med: 0.32 Max: 0.37
Current: 0.28

During the past 13 years, the highest Equity to Asset Ratio of Grifols was 0.37. The lowest was 0.28. And the median was 0.32.

GRFS's Equity-to-Asset is ranked worse than
82.06% of 1087 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs GRFS: 0.28

Grifols Equity-to-Asset Historical Data

The historical data trend for Grifols's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

0.31

0.33

0.29

0.28

Grifols Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Equity-to-Asset																-	0.29	0.27	0.28	0.28

Competitive Comparison

For the Drug Manufacturers - General subindustry, Grifols's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Grifols Equity-to-Asset Distribution

For the Drug Manufacturers industry and Healthcare sector, Grifols's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Grifols's Equity-to-Asset falls into.

Grifols Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Grifols's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	6396.563	/	23256.156
	=	0.28

Grifols's Equity to Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

Equity to Asset (Q: Sep. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	6539.037	/	23548.023
	=	0.28

Grifols (NAS:GRFS) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Grifols Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Grifols's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Grifols (Grifols) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (NAS:GRFS) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

GIKLY:USA GIFOF:USA GIFLF:USA GRFP:Mexico GRFe:UK GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain GRF:Spain G0F0:Germany G0F:Germany G0FB:Germany OZTA:Germany OZTA:Germany G0FB:Germany

Address

Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174

Website

https://www.grifols.com

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.